Bacteria Use a Receptor Protein to Shield Themselves from the Antimicrobial Peptide Lactoferricin | Research

The takeaway

Lactoferrin binding protein B (LbpB) from pathogenic bacteria protects them against killing by the antimicrobial peptide lactoferricin, likely through negatively charged amino acid clusters that neutralize the peptide's positive charge.

LbpB from 2 species protects against lactoferricin
Lactoferrin binding protein B from both Moraxella and Neisseria species protected bacteria against lactoferricin killing — demonstrating that resistance to this antimicrobial peptide is a conserved feature among mucosal pathogens.

What the researchers found

Lactoferrin binding protein B (LbpB) from two different Gram-negative bacterial species (Moraxella and Neisseria) provided protection against killing by human lactoferricin. The proposed mechanism involves clusters of negatively charged amino acids in the C-terminal lobe of LbpB that electrostatically interact with the positively charged (cationic) lactoferricin peptide, effectively sequestering it before it can insert into and disrupt the bacterial membrane.

The study also investigated the prevalence and sequence diversity of lactoferrin receptors across bacterial species, suggesting that LbpB-mediated defense against antimicrobial peptides is a widespread strategy among mucosal pathogens.

Why it matters

Understanding how bacteria resist antimicrobial peptides is critical for developing peptide-based antibiotics. Lactoferricin is one of the most studied antimicrobial peptides, and the discovery that bacteria can neutralize it through a specific receptor protein reveals a vulnerability in peptide-based immune defense. This knowledge could guide the design of modified antimicrobial peptides that evade LbpB-mediated resistance, or the development of combination therapies that block LbpB to restore lactoferricin's effectiveness.

How the study worked

Researchers tested LbpB from two bacterial species for its ability to protect against human lactoferricin killing activity using antimicrobial sensitivity assays. They analyzed the amino acid sequences of LbpB proteins across multiple bacterial species to identify conserved features, particularly the negatively charged amino acid clusters in the C-terminal region proposed to mediate peptide neutralization.

What this study cannot tell us

The study tested LbpB from only two bacterial species, and the protective mechanism (electrostatic charge neutralization) is proposed based on sequence analysis rather than direct structural evidence. The in vivo relevance of LbpB-mediated protection — whether it meaningfully affects infection outcomes in humans — was not assessed. The study focused on lactoferricin specifically and did not test whether LbpB protects against other cationic antimicrobial peptides.

How to read the evidence

This is a laboratory-based study using in vitro antimicrobial assays and bioinformatic sequence analysis. While the findings are mechanistically significant, the in vivo relevance and clinical implications remain to be established.

When this study was published

Published in 2012, this study was among the early demonstrations that bacteria can specifically resist antimicrobial peptides. The concept has since been confirmed and expanded by subsequent research, making this a foundational finding in the field.

The bigger picture

This study challenges the early assumption that bacteria cannot develop resistance to antimicrobial peptides. The LbpB-lactoferricin interaction represents a sophisticated evolutionary strategy: bacteria that live on mucosal surfaces (respiratory and genitourinary tracts) encounter lactoferrin-derived peptides constantly, creating selective pressure for resistance mechanisms. Understanding these mechanisms is essential as the field pursues antimicrobial peptides as alternatives to conventional antibiotics.

Questions still open

Could antimicrobial peptides be modified to avoid LbpB-mediated neutralization while retaining their antibacterial activity?
Does LbpB protect bacteria against other human cationic antimicrobial peptides beyond lactoferricin, such as LL-37 or defensins?
Would blocking LbpB with antibodies or small molecules restore lactoferricin sensitivity in resistant bacteria?

Common questions

What is lactoferricin and how does it normally fight infections?

Lactoferricin is a short antimicrobial peptide naturally produced when the immune protein lactoferrin is broken down by enzymes at sites of infection and inflammation. It has a strong positive electrical charge that allows it to stick to and punch holes in the negatively charged membranes of bacteria, killing them. It's one of the body's built-in defenses against infections on mucosal surfaces like the respiratory and urinary tracts.

How do bacteria resist antimicrobial peptides?

This study shows one mechanism: bacteria produce a surface protein (LbpB) with clusters of negative charges that act like an electrostatic 'sponge,' capturing the positively charged lactoferricin before it can reach and damage the bacterial membrane. It's essentially a molecular shield. Other bacteria use different strategies, like modifying their membrane charge or producing enzymes that degrade antimicrobial peptides.

Read the original research

The role of lactoferrin binding protein B in mediating protection against human lactoferricin.

Biochemistry and cell biology = Biochimie et biologie cellulaire, 90(3), 417-23

View on PubMed ↗Publisher’s paper ↗

Citation

Morgenthau, Ari; Livingstone, Margaret; Adamiak, Paul; Schryvers, Anthony B. (2012). The role of lactoferrin binding protein B in mediating protection against human lactoferricin.. Biochemistry and cell biology = Biochimie et biologie cellulaire, 90(3), 417-23. https://doi.org/10.1139/o11-074